Delcath Systems (NASDAQ:DCTH) Rating Lowered to Hold at Wall Street Zen

Delcath Systems (NASDAQ:DCTH) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

DCTH has been the topic of several other research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Delcath Systems in a research report on Wednesday, October 8th. Stephens restated an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research report on Monday, June 23rd. Finally, HC Wainwright lifted their price target on shares of Delcath Systems from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

Delcath Systems Price Performance

NASDAQ DCTH opened at $11.35 on Friday. Delcath Systems has a 12 month low of $8.35 and a 12 month high of $18.23. The firm has a market capitalization of $397.02 million, a PE ratio of 227.00 and a beta of 0.84. The company’s 50 day simple moving average is $10.91 and its 200 day simple moving average is $12.43.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. The business had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. Sell-side analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Delcath Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in Delcath Systems during the 2nd quarter worth approximately $25,000. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $26,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $40,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $42,000. Finally, Legal & General Group Plc acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $46,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.